Chapter

Mesenchymal Stem Cells - Basics and Clinical Application II

Volume 130 of the series Advances in Biochemical Engineering/Biotechnology pp 1-17

Date:

Engineered MSCs from Patient-Specific iPS Cells

  • Irina EberleAffiliated withJunior Research Group Stem Cell Biology, OE 8881, Cluster-of-Excellence REBIRTH, Hannover Medical SchoolDRK-Institute of Transfusion Medicine and Immune Hematology
  • , Mohsen MoslemAffiliated withJunior Research Group Stem Cell Biology, OE 8881, Cluster-of-Excellence REBIRTH, Hannover Medical School
  • , Reinhard HenschlerAffiliated withDRK-Institute of Transfusion Medicine and Immune Hematology
  • , Tobias CantzAffiliated withJunior Research Group Stem Cell Biology, OE 8881, Cluster-of-Excellence REBIRTH, Hannover Medical School Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Mesenchymal stroma/stem cells (MSCs) represent a heterogenic cell population that can be isolated from various tissues of the body or can be generated from pluripotent stem cells by in vitro differentiation. Various promising pre-clinical and clinical studies suggest that MSCs might stimulate endogenous regeneration and/or act as anti-inflammatory agents, which could be of high therapeutic relevance for a number of diseases, including graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, inflammatory bowel diseases, or some forms of liver failure. Notably, conflicting results of various studies illustrated that the source of MSCs, the cultivation condition, and the way of administration have important effects on the desired clinical effect. Some of the involved molecular pathways have recently been elucidated and an artificial modulation of these pathways by engineered MSCs might result in superfunctional MSCs for enhanced endogenous regeneration or anti-inflammatory response. In this review, we summarize important findings of conventional MSCs for applications in gastroenterology and we describe the state-of-the-art for the generation of patient-derived iPS cells that eventually might provide genetically engineered superfunctional iPS cells for advanced cell therapies.

Graphical Abstract

https://static-content.springer.com/image/chp%3A10.1007%2F10_2012_156/MediaObjects/300442_1_En_156_Figa_HTML.gif

Keywords

Cell transplantation Induced pluripotent stem cells (iPSC) Inflammatory bowel diseases Liver diseases Mesenchymal stromal (stem) cells (MSC)